Estonia - estoniană - Ravimiamet

livisto int'l s.l. - enrofloksatsiin - suukaudne suspensioon - 25mg 1ml 8.5ml 1tk

Estonia - estoniană - Ravimiamet

lex ano uab - mikonasool - suukaudne geel - 20mg 1g 40g 1tk

Estonia - estoniană - Ravimiamet

labiana life sciences s.a. - ketoprofeen - süstelahus - 150mg 1ml 100ml 10tk; 150mg 1ml 50ml 12tk; 150mg 1ml 250ml 1tk; 150mg 1ml 250ml 10tk; 150mg 1ml 100ml 1tk

Estonia - estoniană - Ravimiamet

labiana life sciences s.a. - tolfenaamhape - süstelahus - 40mg 1ml 50ml 1tk; 40mg 1ml 250ml 1tk; 40mg 1ml 100ml 1tk; 40mg 1ml 20ml 1tk

Estonia - estoniană - Ravimiamet

ideal trade links uab - mikonasool - suukaudne geel - 20mg 1g 40g 1tk

Estonia - estoniană - Ravimiamet

stada arzneimittel ag - diklofenak - geel - 23,2mg 1g 60g 1tk; 23,2mg 1g 100g 1tk; 23,2mg 1g 120g 1tk; 23,2mg 1g 150g 1tk

Estonia - estoniană - Ravimiamet

labiana life sciences s.a. - buprenorfiin - süstelahus - 0,3mg 1ml 10ml 1tk; 0,3mg 1ml 10ml 10tk

Uniunea Europeană - estoniană - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaktsiinid - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.